Cambridge Investment Research Advisors
RPRX icon

Cambridge Investment Research Advisors’s Royalty Pharma RPRX Stock Holding History

Cambridge Investment Research Advisors’s Portfolio RPRX Stock Details RPRX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$307K Buy
5,472
+399
+8% +$20.8K ﹤0.01% 3426
2026
Q1 		$243K Buy
+5,073
New +$222K ﹤0.01% 3483

Other funds holding RPRX

Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
Capital International Investors
Capital International Investors Los Angeles, California $484B AUM 34.9% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
Swedbank
Swedbank Stockholm, Sweden $116B AUM 46.87% 1-Year Est. Return
Baillie Gifford & Co
Baillie Gifford & Co Edinburgh, United Kingdom $110B AUM 4.8% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Cambridge Investment Research Advisors's RPRX Position: Q2 2026 in Review

Cambridge Investment Research Advisors increased its Royalty Pharma (RPRX) stake by 7.9% in Q2 2026, buying an estimated $20.8K and bringing the position to 5,472 shares worth $307K. The position accounts for ﹤0.01% of the portfolio, ranked #3426.

Cambridge Investment Research Advisors first reported a position in RPRX in Q1 2026 and has held it in 2 quarters since. 647 funds tracked by Wall St. Rank hold RPRX as of Q2 2026.

  • Cambridge Investment Research Advisors held 5,472 shares of Royalty Pharma worth $307K as of Q2 2026.
  • Cambridge Investment Research Advisors bought 399 Royalty Pharma shares in Q2 2026, an estimated $20.8K.
  • Royalty Pharma made up ﹤0.01% of Cambridge Investment Research Advisors's portfolio in Q2 2026, its #3426 holding.
  • Cambridge Investment Research Advisors first reported a position in Royalty Pharma in Q1 2026 and has held it in 2 quarters since.
  • 647 funds tracked by Wall St. Rank held Royalty Pharma as of Q2 2026.

Based on Cambridge Investment Research Advisors's 13F filing for Q2 2026, filed 27 Jul 2026.